Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells

Molecular and Cellular Biology

Volumn 21, Issue 24, 2001, Pages 8471-8482

  Deeble, P D ^a   Murphy, D J ^a   Parsons, S J ^a   Cox, M E ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANDROGEN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; FORSKOLIN; INTERLEUKIN 6; NEUROPEPTIDE; NICOTINIC RECEPTOR; TUBULIN;

ARTICLE; CANCER CELL CULTURE; CANCER REGRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN CELL; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

BROMODEOXYURIDINE; BUTADIENES; CELL DIFFERENTIATION; CELL DIVISION; CHLORAMPHENICOL O-ACETYLTRANSFERASE; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; EPINEPHRINE; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-6; MALE; MAP KINASE SIGNALING SYSTEM; MITOSIS; NITRILES; PHENOTYPE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-FOS; RIBONUCLEASES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0035197917     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.21.24.8471-8482.2001     Document Type: Article

References (51)

1. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma
2. Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia
3. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP
4. Multiple sequence elements of a single functional class are required for cyclic AMP responsiveness of the mouse c-fos promoter
5. Transcriptional regulation of neuronal nicotinic acetylcholine receptor genes. Functional interactions between Sp1 and the rat beta4 subunit gene promoter
6. Sp1 and Sp3 regulate expression of the neuronal nicotinic acetylcholine receptor beta4 subunit gene
7. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells
8. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate
9. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo
10. Elevation of cyclic adenosine 3′,5′-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells
11. Immunophilin ligands and GDNF enhance neurite branching or elongation from developing dopamine neurons in culture
12. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells
13. Activated 3′,5′-cyclic AMP-dependent protein kinase is sufficient to induce neuroendocrine-like differentiation of the LNCaP prostate tumor cell line
14. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: Implications for prostate cancer progression
15. Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6
16. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP
17. Modulation of neuroendocrine differentiation in prostate cancer by interleukin-1 and -2
18. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer
19. A 42-kD tyrosine kinase substrate linked to chromaffin cell secretion exhibits an associated MAP kinase activity and is highly related to a 42-kD mitogen-stimulated protein in fibroblasts
20. Induction of c-fos mRNA and AP-1 DNA-binding activity by cAMP in cooperation with either the adenovirus 243- or the adenovirus 289-amino acid E1A protein
21. Interleukin 6 and its receptor: Ten years later
22. Effect of phosphorylation on activities of Rap1A to interact with Raf-1 and to suppress Res-dependent Raf-1 activation
23. Parathyroid hormone-related protein: A potential autocrine growth regulator in human prostate cancer cell lines
24. Class III beta-tubulin isotype (beta III) in the adrenal medulla II. Localization in primary human pheochromocytomas
25. Class III beta-tubulin isotype (beta III) in the adrenal medulla III. Differential expression of neuronal and glial antigens identifies two distinct populations of neuronal and glial-like (sustentacular) cells in the PC12 rat pheochromocytoma cell line maintained in a Gelfoam matrix system
26. Class III beta-tubulin isotype (beta III) in the adrenal medulla I. Localization in the developing human adrenal medulla
27. Interleukin-6 and its receptor: A paradigm for cytokines
28. Effects of serotonin on neurite outgrowth from thalamic neurons in vitro
29. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway
30. Nicotine stimulates secretion of both catecholamines and acetylcholinesterase from cultured adrenal chromaffin cells
31. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro
32. Integration of growth factor signals at the c-fos serum response element
33. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells
34. Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3′-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells
35. Bone morphogenetie protein-2 promotes dissociated effects on the number and differentiation of cultured ventral mesencephalic dopaminergic neurons
36. A common nuclear signal transduction pathway activated by growth factor and cytokine receptors
37. Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations
38. Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer
39. Transdifferentiation of cultured human prostate cells to a neuroendocrine cell phenotype in a hormone-depleted medium
40. Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia
41. Interleukin-6: Structure-function relationships
42. c-Raf-mediated inhibition of epidermal growth factor-stimulated cell migration
43. STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP
44. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells
45. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer
46. Cathepsin D and chromogranin a as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate
47. Interleukin-6: A candidate mediator of human prostate cancer morbidity
48. cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway
49. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation
50. The cyclic adenosine monophosphate-dependent protein kinase (PKA) is required for the sustained activation of mitogen-activated kinases and gene expression by nerve growth factor
51. Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR